abusesaffiliationarrow-downarrow-leftarrow-rightarrow-upattack-typeburgerchevron-downchevron-leftchevron-rightchevron-upClock iconclosedeletedevelopment-povertydiscriminationdollardownloademailenvironmentexternal-linkfacebookfiltergenderglobegroupshealthC4067174-3DD9-4B9E-AD64-284FDAAE6338@1xinformation-outlineinformationinstagraminvestment-trade-globalisationissueslabourlanguagesShapeCombined Shapeline, chart, up, arrow, graphLinkedInlocationmap-pinminusnewsorganisationotheroverviewpluspreviewArtboard 185profilerefreshIconnewssearchsecurityPathStock downStock steadyStock uptagticktooltiptwitteruniversalityweb
Article

15 Nov 2007

Author:
FDA News [USA]

AIDS Groups File Complaint Over Merck AIDS Drug Access in South Africa

Two AIDS activist groups filed a complaint in South Africa against Merck, claiming the company does not grant enough licenses to generic companies to sell its AIDS drug Stocrin. Merck’s actions have prevented access to cheaper, generic versions of Stocrin (efavirenz), according to a complaint filed by the AIDS Law Project and the Treatment Action Campaign in the Competition Commission of South Africa. The company has violated South Africa’s Competition Act, the groups say…The complaint requests a compulsory license…